Drugs commonly used clinically for treating type 2 diabetes can also reduce PAI-1, a phenomenon primarily associated with lower insulin precursors and improved insulin resistance, expanding the evidence for the clinical use of these drugs. Here, SERPINE1 is linked to Insulin resistance.